FDA-approved. A product approved under an NDA or BLA has labelling, manufacturing standards and post-market reporting tied to that approval. You can look it up on Drugs@FDA.

Compounded. FDA explains that compounded drugs can serve patients who need a different strength, form or allergen-free version when an approved product does not meet the need — and that compounded drugs are not FDA-approved (FDA compounding overview for pharmacists).

Those are not the same category. "Same molecule name" does not mean "same reviewed product".

FDA maintains information on certain bulk drug substances that may present significant safety risks when used in compounding (FDA page). Coaches should not invent a safety ranking; point clients to FDA and to their own clinician.

Federal Register notice 2026-22192 describes an enforcement-discretion policy regarding 503A compounding with certain peptide bulk drug substances (FR document). It is not FDA approval of those peptides, not a final bulks list decision, and not permission for coaches to procure or recommend them.

Clients often collapse "peptide" and "GLP-1" into one shopping question. For semaglutide and tirzepatide specifically, FDA's 1 Apr 2026 update states they do not currently appear on the 503B bulks list or on FDA's drug shortage list (FDA). A coach's line is: medicine supply and substitution questions go to the prescriber and pharmacist — not to a coach with a discount code.

1. "I don't source, sell or dose any medicine or peptide. That stays with your clinician and pharmacy."
2. "FDA-approved and compounded are different pathways. Approved products are listed on Drugs@FDA; compounded products are not FDA-approved as copies of those brands."
3. "If cost is the issue, ask your prescriber and insurer about covered options, patient-assistance programmes or clinically appropriate alternatives. I can help you prepare questions for that visit."
4. "If someone online offers vials, stacks or 'research' peptides with a checkout link, that is a red flag for my practice. I won't affiliate with it."
5. "I can still coach sleep, protein, strength training and follow-through on whatever plan your clinician sets."

• Place orders, share vendor lists, or earn affiliate fees on peptides or compounded GLP-1 products.
• Tell a client a compounded product is "the same" as an approved drug.
• Adjust dose, suggest splitting pens, or coach injection technique as if supervising medical use.
• Treat FR 2026-22192 as a product endorsement.

Scope baseline: NBHWC scope of practice.

Level 1 free. Level 3 covers what peptides are and evidence quality. Level 4 covers the HHS 503A peptide policy module and ethical marketing. Level 5 runs grey-market case studies. Profile: /coach. We do not promise income or client results.

Marketing uses the same molecule names for approved pens and for compounded or grey-market vials. Clients hear "semaglutide" and assume every seller is equivalent. Your job is to reopen the categories: approved product with labelling and manufacturing tied to an NDA/BLA versus a compounded preparation that is not FDA-approved as a copy of that brand.

If a coach earns a commission on peptide checkouts, that is a conflict and usually a scope violation for health coaches who claim they do not practise pharmacy. Refuse affiliate codes. Refuse "DM me for my source". Refuse before-and-after posts that imply you provided the drug.

Keep a one-page script in your onboarding packet. When a client asks for sourcing, send the written scope, decline, and offer to help prepare questions for their clinician visit. That paper trail protects the client and you.